Synthesis and Biological Evaluation of New cis-Restricted Triazole Analogues of Combretastatin A-4
Molecules · 2025
DOI: 10.3390/molecules30020317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Lidia Prieto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic Chemistry, University of Valencia, E-46100 Burjassot, Spain. Hauptthemen laut MEDLINE: Triazoles, Stilbenes, Antineoplastic Agents, Bibenzyls. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Spanish Ministerio de Ciencia, Innovación y Universidades.
Abstract (Originalsprache)
The natural products combretastatins A-1 and A-4 are potent antimitotic and vascular-disrupting agents through their binding at the colchicine site in tubulin. However, these compounds suffer from a low water solubility and a tendency to isomerize to the inactive trans stilbenes. In this study, we have prepared a series of 18 cis-restricted triazole analogues of combretastatin A-4 (CA-4), maintaining, in all cases, the 3,4,5-trimethoxy phenyl ring A, with the aim of investigating the substitution pattern on the B-ring in a systematic way. To this end, cytotoxic activities of the cis-restricted analogues of CA-4 prepared were determined in two tumor cell lines, namely, HT-29 and A-549, as well as in the non-tumor cell line HEK-293, to pre-evaluate the selectivity profile of the compounds for the tumor cell lines. The main conclusion was the essential presence of methoxyl or ethoxyl groups at the para position of the B-ring in order to obtain good antitumor activities. Thus, the more active compounds in our study displayed IC50 values in the nanomolar range for the tumor cell lines but not for the normal cells. Consequently, these triazole analogues of CA-4 could serve as promising alternatives to the natural product, although further studies about their biological activity are essential in order to fully determine their viability as therapeutic agents in the treatment of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Organic Chemistry, University of Valencia, E-46100 Burjassot, Spain.
- Department of Organic and Inorganic Chemistry, University Jaume I, E-12071 Castellón, Spain.
ORCID-Profile: Marcos Escolano, Eva Falomir, Santiago Díaz-Oltra
Förderung
- Ministerio de Ciencia, Innovación y Universidades
- Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital
- Spanish Ministerio de Ciencia, Innovación y Universidades
- Conselleria d’Innovació, Universitats, Ciència i Societat Digital of the Generalitat Valenciana
- European Union
- Spanish Ministerio de Educación, Cultura y Deporte
Zitieren
APA
Prieto, L., Gaviña, D., Escolano, M., Cánovas-Belchí, M., Sánchez-Roselló, M., Del Pozo, C., Falomir, E., & Díaz-Oltra, S. (2025). Synthesis and Biological Evaluation of New cis-Restricted Triazole Analogues of Combretastatin A-4. Molecules. https://doi.org/10.3390/molecules30020317
Vancouver
Prieto L, Gaviña D, Escolano M, Cánovas-Belchí M, Sánchez-Roselló M, Del Pozo C, et al. Synthesis and Biological Evaluation of New cis-Restricted Triazole Analogues of Combretastatin A-4. Molecules. 2025. doi:10.3390/molecules30020317
BibTeX
@article{Prieto2025,
author = {Prieto, Lidia and Gaviña, Daniel and Escolano, Marcos and Cánovas-Belchí, María and Sánchez-Roselló, María and Del Pozo, Carlos and Falomir, Eva and Díaz-Oltra, Santiago},
title = {Synthesis and Biological Evaluation of New cis-Restricted Triazole Analogues of Combretastatin A-4},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30020317}
}
EUVIMED